A new report estimates that more than 8,300 U.S. patients a year are not receiving full treatments for their bladder cancer due to a shortage of a drug called BCG.
A new report estimates that more than 8,300 U.S. patients a year are not receiving full treatments for their bladder cancer due to a shortage of a drug called BCG.